Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease:A review of the literature  

作　　者：Thais Gagno Grillo Caroline Ferreira da Silva Mazeto Pupo Silveira Ana Elisa Valencise Quaglio Renata de Medeiros Dutra Julio Pinheiro Baima Silmeia Garcia Zanati Bazan Ligia Yukie Sassaki 

机构地区：[1]Department of Internal Medicine,Medical School,São Paulo State University,Botucatu,Botucatu 18618686,Brazil [2]Department of Biophysics and Pharmacology,Institute of Biosciences,São Paulo State University,Botucatu,Botucatu 18618689,Brazil

出　　处：《World Journal of Cardiology》2023年第5期217-228,共12页世界心脏病学杂志（英文版）（电子版）

摘　　要：Tumor necrosis factor inhibitors(anti-TNFs)are widely used therapies for the treatment of inflammatory bowel diseases(IBD);however,their administration is not risk-free.Heart failure(HF),although rare,is a potential adverse event related to administration of these medications.However,the exact mechanism of development of HF remains obscure.TNFαis found in both healthy and damaged hearts.Its effects are concentration-and receptor-dependent,promoting either cardio-protection or cardiomyocyte apoptosis.Experimental rat models with TNFαreceptor knockout showed increased survival rates,less reactive oxygen species formation,and improved diastolic left ventricle pressure.However,clinical trials employing anti-TNF therapy to treat HF had disappointing results,suggesting abolishment of the cardioprotective properties of TNFα,making cardiomyocytes susceptible to apoptosis and oxidation.Thus,patients with IBD who have risk factors should be screened for HF before initiating anti-TNF therapy.This review aims to discuss adverse events associated with the administration of anti-TNF therapy,with a focus on HF,and propose some approaches to avoid cardiac adverse events in patients with IBD.

关 键 词：Tumor necrosis factor inhibitors Inflammatory bowel disease Heart failure Adverse event TNFαreceptor 

分 类 号：R541.6[医药卫生—心血管疾病]